3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Nasopharyngeal Carcinoma
18
Esophageal Neoplasms
12
Squamous Cell Carcinoma of Head and Neck
11
Esophageal Squamous Cell Carcinoma
11
Uterine Cervical Neoplasms
9
Head and Neck Neoplasms
9
Carcinoma, Non-Small-Cell Lung
9
Pancreatic Neoplasms
8
Stomach Neoplasms
4
Neoplasms
3
Colorectal Neoplasms
3
Recurrence
2
Pancreatic cancer, adult
2
Neoplasm Metastasis
2
Nasopharyngeal Neoplasms
2
Lung Neoplasms
2
Diffuse Intrinsic Pontine Glioma
2
Carcinoma
2
Adenocarcinoma
2
Uterine Cervical Dysplasia
1
Urinary Bladder Neoplasms
1
Squamous Cell Carcinoma of Anal Canal
1
Solid Tumors
1
Solid Tumor
1
Penile Neoplasms
1
Pathologic Complete Response
1
Pancreatic Cancer Resectable
1
Oropharyngeal Neoplasms
1
Nasopharyngeal Diseases
1
NSCLC
1
Interventions
Gemcitabine
9
130-nm albumin-bound paclitaxel
6
S 1 (combination)
4
Albumin-Bound Paclitaxel
4
toripalimab
3
Taxes
3
Nivolumab
2
Injections
2
Drug Therapy
2
surufatinib
1
penpulimab
1
pegylated granulocyte colony-stimulating factor
1
paricalcitol
1
nimotuzumab
1
irinotecan sucrosofate
1
gimeracil
1
fluzoparib
1
envafolimab
1
endostar protein
1
conteltinib
1
camrelizumab
1
cabiralizumab
1
apatinib
1
Tegafur
1
Simvastatin
1
Radiosurgery
1
Paclitaxel
1
Oxaliplatin
1
Metformin
1
Leucovorin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Advanced Pancreatic Cancer
×
nimotuzumab
×
Clear all
NCT06422156
2024-05-20
Nim-PC-28
Peking University Third Hospital
Phase 2
Not yet recruiting
73 enrolled